ClinicalTrials.gg
CompletedNCT03717155Updated Jun 6, 2022Results posted

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

A Phase 2 interventional study of Avelumab and Cetuximab in Squamous Non-Small Cell Lung Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-06.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, 1 of them phase 3. avelumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 15
43 · median 67
Started
2018
with 3 others
Phase 2
3 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Merck KGaA, Darmstadt, Germany

Among the 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 4 that started in 2018, is one of 3 in phase 2, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About avelumab

avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung cancer (NSCLC).

03

Conditions studied

  • Squamous Non-Small Cell Lung Cancer

Keywords

  • Avelumab
  • Cetuximab
  • Cisplatin
  • Gemcitabine
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed Stage IV or recurrent (Stage IV) NSCLC of squamous histology
  • Availability of formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue or a minimum of 15 (preferably 25) unstained tumor slides (cut within 1 week) suitable for Programmed death ligand 1 () expression and epidermal growth factor receptor (EGFR) expression/amplification assessments
  • At least 1 per (RECIST) v1.1 criteria
  • Performance Status (ECOG PS) of 0 to 1 at study entry
  • Adequate hematological, hepatic and renal function
  • Estimated of at least 3 months
  • Can give signed
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants whose tumor disease harbors an activating EGFR mutation or ALK rearrangement. Participants with tumors of unknown EGFR or ALK status will require testing only in never smokers
  • All participants with with protocol defined exceptions
  • Previous malignant disease (other than NSCLC) within the last 5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the participant was deemed to have been cured with no additional therapy required or anticipated to be required
  • Active infection requiring systemic therapy
  • Known history of or known acquired immunodeficiency syndrome
  • virus (HBV) or virus (HCV) infection at screening (positive HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test positive)
  • Active disease that might deteriorate when receiving an immunostimulatory agent
  • Interstitial parenchymal lung disease
  • Pregnancy or lactation
  • Known alcohol or drug abuse as determined by the Investigator
  • History of uncontrolled intercurrent illness
  • (that is active) cardiovascular disease
  • Known history of inflammatory colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis
  • Any psychiatric condition that would prohibit the understanding or rendering of or that would limit compliance with study requirements
  • Prior/Concomitant Therapy as described in protocol
  • Use of any drug within 28 days before the start of study treatment
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Avelumab and Cetuximab

    Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.

    Drug: Avelumab · Drug: Cetuximab · Drug: Gemcitabine · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.

  • Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.

  • Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.

  • Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.

  • In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator

    Confirmed BOR was defined as the percentage of participants who achieved confirmed complete responses (CR) or partial response (PR), according to RECIST version 1.1 assessed by the Investigator.CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Stable disease (SD)= Neither sufficient increase to qualify for progression of disease (PD) nor sufficient shrinkage to qualify for PR. PD: At least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Confirmed CR=as at least two determinations of CR at least 4 weeks apart with no PD. Confirmed PR=as at least 2 determinations of PR or better (PR followed by PR or PR followed by CR), at least 4 weeks apart (not qualifying for a CR) with no PD in between. Percentage of Participants with confirmed BOR were reported.

    Time frame: Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 612 days)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs)

    Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug.Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious and non-serious TEAEs. irAEs included AEs that matches a preferred term on the list of pre-selected MedDRA terms. AEs with relationship to study treatment are reported as Treatment-related AEs. Treatment related AEs with grade 3 or more is also reported.

    Time frame: Time from the first dose of study drug assessed up to (941 days)

  2. Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Progression free survival (PFS) is defined as the time (in months) from first treatment day to the date of the first documentation of objective progression of disease (PD) according to RECIST version 1.1 assessed by Investigator, or death due to any cause, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 737 days)

  3. Duration of Response (DOR)

    DOR is defined for participants with confirmed complete response (CR) or partial response (PR), as the time from first documentation of confirmed response to the date of first documentation of progression of disease (PD) according to RECIST version 1.1 (assessed by Investigator) or death due to any cause or tumor assessment. Duration of objective response was assessed using Kaplan-Meier analysis. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 612 days)

  4. Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab

    Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed Avelumab concentration-time data.

    Time frame: Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337

  5. Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab

    Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed cetuximab concentration-time data.

    Time frame: Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337

  6. Serum Trough Concentration Levels (Ctrough) of Avelumab

    Ctrough is the serum concentration observed immediately before next dosing.

    Time frame: Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337

  7. Serum Trough Concentration Levels (Ctrough) of Cetuximab

    Ctrough is the serum concentration observed immediately before next dosing.

    Time frame: Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337

  8. Overall Survival (OS)

    OS is defined as the time from the first treatment day to the date of death due to any cause. Overall survival was assessed using Kaplan-Meier analysis.

    Time frame: Time from the first dose of study drug until occurrence of death due to any cause (assessed up to 941 days)

  9. Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab

    The detection of antibodies to avelumab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of avelumab were reported.

    Time frame: Pre-dose up to 149 days

  10. Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab

    The detection of antibodies to cetuximab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of cetuximab were reported.

    Time frame: Pre-dose up to 149 days

07

Results

Posted Nov 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneAvelumab and Cetuximab
Started43
Completed43
Not completed0

Outcome measures

PrimaryPercentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator

Confirmed BOR was defined as the percentage of participants who achieved confirmed complete responses (CR) or partial response (PR), according to RECIST version 1.1 assessed by the Investigator.CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Stable disease (SD)= Neither sufficient increase to qualify for progression of disease (PD) nor sufficient shrinkage to qualify for PR. PD: At least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Confirmed CR=as at least two determinations of CR at least 4 weeks apart with no PD. Confirmed PR=as at least 2 determinations of PR or better (PR followed by PR or PR followed by CR), at least 4 weeks apart (not qualifying for a CR) with no PD in between. Percentage of Participants with confirmed BOR were reported.

Time frame:
Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 612 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator
percentage of participantsAvelumab and Cetuximab
Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator34.9 (21.0 to 50.9)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs)

Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug.Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious and non-serious TEAEs. irAEs included AEs that matches a preferred term on the list of pre-selected MedDRA terms. AEs with relationship to study treatment are reported as Treatment-related AEs. Treatment related AEs with grade 3 or more is also reported.

Time frame:
Time from the first dose of study drug assessed up to (941 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs)
ParticipantsAvelumab and Cetuximab
TEAEs41
Treatment-Related AEs38
Treatment Related Grade>=3 TEAEs24
irTEAEs13
SecondaryProgression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Progression free survival (PFS) is defined as the time (in months) from first treatment day to the date of the first documentation of objective progression of disease (PD) according to RECIST version 1.1 assessed by Investigator, or death due to any cause, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 737 days)
Reported as:
Median · Months
Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
MonthsAvelumab and Cetuximab
Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.16.1 (4.3 to 9.0)
SecondaryDuration of Response (DOR)

DOR is defined for participants with confirmed complete response (CR) or partial response (PR), as the time from first documentation of confirmed response to the date of first documentation of progression of disease (PD) according to RECIST version 1.1 (assessed by Investigator) or death due to any cause or tumor assessment. Duration of objective response was assessed using Kaplan-Meier analysis. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 612 days)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsAvelumab and Cetuximab
Duration of Response (DOR)7.1 (4.2 to 12.5)
SecondaryImmediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab

Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed Avelumab concentration-time data.

Time frame:
Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab
microgram per milliliter (mcg/mL)Avelumab and Cetuximab
Day 1206 ± 26.6
Day 8243 ± 23.8
Day 22234 ± 24.1
Day 29282 ± 26.8
Day 43237 ± 30.5
Day 50259 ± 38.9
Day 64214 ± 67.6
Day 71244 ± 43.8
Day 85223 ± 33.3
Day 99202 ± 62.4
Day 113234 ± 29.7
Day 127222 ± 55.1
Day 169245 ± 20.8
Day 253249 ± 28.7
Day 337246 ± 38.6
SecondaryImmediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab

Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed cetuximab concentration-time data.

Time frame:
Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337
Reported as:
Geometric mean · mcg/mL
Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab
mcg/mLAvelumab and Cetuximab
Day 1109 ± 50.7
Day 8198 ± 86.6
Day 22124 ± 54.4
Day 29260 ± 25.0
Day 43154 ± 32.7
Day 50238 ± 28.9
Day 64159 ± 36.1
Day 71262 ± 25.1
Day 85239 ± 38.4
Day 99252 ± 21.1
Day 113250 ± 20.4
Day 127245 ± 55.8
Day 169297 ± 29.2
Day 253269 ± 34.4
Day 337304 ± 37.3
SecondarySerum Trough Concentration Levels (Ctrough) of Avelumab

Ctrough is the serum concentration observed immediately before next dosing.

Time frame:
Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337
Reported as:
Geometric mean · mcg/mL
Serum Trough Concentration Levels (Ctrough) of Avelumab
mcg/mLAvelumab and Cetuximab
Day 828.8 ± 82.7
Day 2213.6 ± 97.1
Day 2942.4 ± 147.8
Day 4315.6 ± 115.1
Day 5056.4 ± 77.9
Day 6419.7 ± 145.7
Day 7158.2 ± 62.5
Day 8521.5 ± 70.9
Day 9921.2 ± 75.4
Day 11319.4 ± 78.5
Day 12718.1 ± 107.6
Day 16919.3 ± 67.2
Day 25317.0 ± 80.1
Day 33720.8 ± 55.9
SecondarySerum Trough Concentration Levels (Ctrough) of Cetuximab

Ctrough is the serum concentration observed immediately before next dosing.

Time frame:
Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337
Reported as:
Geometric mean · mcg/mL
Serum Trough Concentration Levels (Ctrough) of Cetuximab
mcg/mLAvelumab and Cetuximab
Day 812.1 ± 90.0
Day 2212.8 ± 63.7
Day 2922.8 ± 73.3
Day 4325.6 ± 103.7
Day 5023.9 ± 118.1
Day 6417.2 ± 157.9
Day 7135.4 ± 110.4
Day 8526.5 ± 119.4
Day 9922.6 ± 117.3
Day 11335.0 ± 59.0
Day 12738.0 ± 63.6
Day 16940.4 ± 62.2
Day 25331.9 ± 237.7
Day 33728.9 ± 204.9
SecondaryOverall Survival (OS)

OS is defined as the time from the first treatment day to the date of death due to any cause. Overall survival was assessed using Kaplan-Meier analysis.

Time frame:
Time from the first dose of study drug until occurrence of death due to any cause (assessed up to 941 days)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAvelumab and Cetuximab
Overall Survival (OS)10.1 (8.6 to 14.5)
SecondaryNumber of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab

The detection of antibodies to avelumab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of avelumab were reported.

Time frame:
Pre-dose up to 149 days
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab
ParticipantsAvelumab and Cetuximab
Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab7
SecondaryNumber of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab

The detection of antibodies to cetuximab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of cetuximab were reported.

Time frame:
Pre-dose up to 149 days
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab
ParticipantsAvelumab and Cetuximab
Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab1

Adverse events

Collected over Time from the first dose of study drug until 941 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avelumab and Cetuximab30/43 (69.8%)20/43 (46.5%)39/43 (90.7%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAvelumab and Cetuximab
Disease progressionGeneral disorders4/43
AnaemiaBlood and lymphatic system disorders2/43
NeutropeniaBlood and lymphatic system disorders1/43
ThrombocytopeniaBlood and lymphatic system disorders1/43
DeathGeneral disorders1/43
Non-cardiac chest painGeneral disorders1/43
Anaphylactic reactionImmune system disorders1/43
Lower respiratory tract infectionInfections and infestations1/43
PneumoniaInfections and infestations1/43
Blood creatinine increasedInvestigations1/43
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAvelumab and Cetuximab
RashSkin and subcutaneous tissue disorders22/43
AnaemiaBlood and lymphatic system disorders19/43
HypomagnesaemiaMetabolism and nutrition disorders16/43
NeutropeniaBlood and lymphatic system disorders15/43
NauseaGastrointestinal disorders12/43
AstheniaGeneral disorders12/43
ThrombocytopeniaBlood and lymphatic system disorders10/43
VomitingGastrointestinal disorders7/43
FatigueGeneral disorders7/43
Decreased appetiteMetabolism and nutrition disorders7/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Avelumab and Cetuximab
Mean63 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Avelumab and Cetuximab
Female8
Male35
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avelumab and Cetuximab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White43
More than one race0
Unknown or Not Reported0
08

Study locations

20 sites
  • Semmelweis Egyetem - Pulmonologiai Klinika
    Budapest, 1125, Hungary
  • Debreceni Egyetem - Tudogyogyaszati Klinika
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly
    Gyor, 9024, Hungary
  • Markusovszky Egyetemi Oktatokorhaz
    Szombathely, 9700, Hungary
  • Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum
    Torokbalint, 2045, Hungary
  • Zala Megyei Szent Rafael Korhaz
    Zalaegerszeg, 8900, Hungary
  • Clinical Center "Bezanijska kosa" - Department of Oncology
    Belgrade, Serbia
  • Clinical Center Kragujevac (no dept.)
    Belgrade, Serbia
  • Institute for Pulmonary Diseases of Vojvodina
    Sremska Kamenica, Serbia
  • Complejo Hospitalario Universitario A Coruña - Servicio de Oncologia
    A Coruña, 15006, Spain
  • Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica
    Barcelona, 08028, Spain
  • Hospital Universitari Vall d'Hebron - Dept of Oncology
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre - Servicio de Oncologia
    Madrid, 28041, Spain
  • Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia
    Madrid, 28050, Spain
  • Hospital Regional Universitario de Malaga
    Málaga, 29010, Spain
  • Hospital Universitario Virgen Macarena - Servicio de Oncologia
    Sevilla, 41009, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica
    Valencia, 46026, Spain
  • Hospital Clinico Universitario Lozano Blesa - Dept of Oncology
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2020, 23 months.

Results were first posted in Nov 2021, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 23 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2018
First posted
Oct 24, 2018
StartActual
Oct 30, 2018
Primary completionActual
Sep 30, 2020
CompletionActual
May 27, 2021
Results first posted
Nov 9, 2021
Last update
Jun 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03717155
Responsible party
Sponsor
First posted
Oct 24, 2018
Start date
Oct 30, 2018
Primary completion
Sep 30, 2020
Completion
May 27, 2021
Results posted
Nov 9, 2021
Last update
Jun 6, 2022

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avelumab · Cetuximab · Gemcitabine · Cisplatin

Start the discussion